Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine

Archives of Medical Research

Volumn 30, Issue 4, 1999, Pages 269-274

  Jochmus, Ingrid ^a   Schäfer, Klaus ^a,b   Faath, Stefan ^a,b   Müller, Martin ^b   Gissmann, Lutz ^a,b  

^a MediGene AG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Cervical cancer; Chimeric virus like particles; Human papillomavirus type 16; Immune therapy; Vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS PROTEIN; VIRUS VACCINE;

ANTIBODY PRODUCTION; DRUG RESEARCH; IMMUNIZATION; NONHUMAN; PROTEIN EXPRESSION; REVIEW; VIRUS EXPRESSION; VIRUS PARTICLE; WART VIRUS;

EID: 0033167196     PISSN: 01880128     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0188-0128(99)00026-3     Document Type: Review

References (31)

1. zur Hausen H. Papillomaviruses and anogenital cancer as a model to understand the role of viruses in human cancer. Cancer Res. 49:1989;4677.
2. Gissmann L. Human papillomaviruses and genital cancer. Semin Cancer Biol. 3:1992;253.
3. Bosch F.X., Manos M.M., Muñoz N., Sherman M., Jansen A.M., Peto J., Schiffman M.H., Moreno V., Kurman R., Shah K.V. Prevalence of human papillomavirus in cervical cancer. a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group J Natl Cancer Inst. 87:1995;796.
4. Altmann A., Gissmann L., Jochmus I. Towards HPV vaccination. Minson A., Neil J., McCrae M. Viruses and Cancer. 1994;Cambridge University Press, Cambridge. 71.p.
5. Fisher S.G., Gissmann L. Convergent infection. human papillomaviruses and human immunodeficiency virus Antibiot Chemother. 46:1994;134.
6. Wideroff L., Schiffman M.H., Hoover R., Tarone R.E., Nonnenmacher B., Hubbert N., Kirnbauer R., Greer C.E., Lorincz A.T., Manos M.M., Glass A.G., Scott D.R., Sherman M.E., Buckland J., Lowy D., Schiller J.T. Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV 16 DNA-positive and -negative women. J Infect Dis. 174:1996;937.
7. Aiba S., Rokugo M., Tagami H. Immunhistologic analysis of the phenomenon of spontaneous regression of numerous flat warts. Cancer. 58:1986;1246.
8. Coleman N., Birley H.D., Renton A.M., Hanna N.F., Ryait B.K., Byrne M., Taylor-Robinson D., Stanley M.A. Immunological events in regressing genital warts. Am J Clin Pathol. 102:1994;768.
9. Knowles G., O'Neil B.W., Campo M.S. Phenotypical characterization of lymphocytes infiltrating regressing papillomas. J Virol. 70:1996;8451.
10. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Din-Demarquet C., Orth G., Schiller J.T., Lowy D.R. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol. 69:1995;3959.
11. Christensen N.D., Reed C.A., Cladel N.M., Han R., Kreider J.W. Immunization with viruslike particles induce long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol. 70:1996;960.
12. Suzich J.A., Ghim S.-J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., Newsome J.A., Jenson A.B., Schlegel R. Systemic immunization with the papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA. 92:1995;11553.
13. Kirnbauer R., Chandrachud L.M., O'Neil B.W., Wagner E.R., Grindlay G.J., Armstrong A., McGarvie G.M., Schiller J.T., Lowy D.R., Campo M.S. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 219:1996;37.
14. Kirnbauer R., Taub J., Greenstone H., Roden R., Dürst M., Gissmann L., Lowy D.R., Shiller J.T. Efficient self-assembly of human papillomavirus type 16 L1 and L1 plus L2 into virus-like particles. J Virol. 67:1993;7203.
15. Mason H.S., Arntzen C.J. Transgenic plants as vaccine production systems. Trends Biotechnol. 13:1995;388.
16. Mason H.S., Ball J.M., Shi J.J., Estes M.K., Arntzen C.J. Expression of Norwalk virus capsid protein in transgenic potato and its oral immunogenicity in mice. Proc Natl Acad Sci U S A. 93:1996;5335.
17. Haq T.A., Mason H.S., Clements J.D., Arntzen C.J. Oral immunization with a recombinant antigen produced in transgenic plants. Science. 268:1995;714.
18. Nardelli-Haefliger D., Roden R.B., Benyacoub J., Sahli R., Kraehenbuhl J.P., Schiller J.T., Lachat P., Potts A., De Grandi P. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun. 65:1997;3328.
19. Darji A., Guzman C.A., Gerstel B., Wachholz P., Timmis K.N., Wehland J., Chakraborty T., Weiss S. Oral somatic transgene vaccination using attenuated Salmonella typhimurium. Cell. 91:1997;765.
20. Campo M.S. Vaccination against papillomavirus in cattle. zur Hausen H. Curr Top Microbiol Immunol 186. Human Pathogenic Papillomaviruses:1994;Springer-Verlag, Berlin. 255.p.
21. Frazer I., Tindle B. Immune response to human papilloma viruses and the prospects for human papillomavirus-specific immunization. zur Hausen H. Curr Top Microbiol Immunol 186. Human Pathogenic Papillomaviruses:1994;Springer-Verlag, Berlin. 217.p.
22. Jensen E.R., Selvakumar R., Shen H., Ahmed R., Wettstein F.O., Miller J.F. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J Virol. 71:1997;8467.
23. von Knebel Doeberitz M., Oltersdorf T., Schwarz E., Gissmann L. Correlation of modified human papillomavirus early gene expression with altered growth properties in C4-I cervical carcinoma cells. Cancer Res. 48:1988;3780.
24. Meneguzzi G., Cerni C., Kieny M.P., Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology. 181:1991;62.
25. Feltkamp M.C.W., Smits H.L., Vierboom M.P.M., Minnaar R.P., de Jongh B.M., Drijhout J.W., ter Schegget J., Melief C.J.M., Kast W.M. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16 transformed cells. Eur J Immunol. 23:1993;2242.
26. Feltkamp M.C.W., Vreugdenhill G.R., Vierboom M.P.M., Ras E., van der Burg S.H., ter Schegget J., Melief C.J.M., Kast W.M. Cytotoxic lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induces tumors. Eur J Immunol. 25:1995;2638.
27. Zhu X., Tommasino M., Vousden K., Sadovnikova F., Rappuoli R., Crawford L., Kast M., Melief C.J., Beverley P.C., Stauss H.J. Both immunization with protein and with recombinant vaccinia virus can stimulate CTL specific for the E7 protein of human papillomavirus 16 in H-2d mice. Scand J Immunol. 47:1995;557.
28. Borysiewicz L.K., Fiander A., Nimako M., Man S., Wilkinson G.W.G., Westmoreland D., Evans A.S., Adams M., Stacey S.N., Boursnell M.E.G., Rutherford E., Hickling J.K., Inglis S.C. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18. E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 347:1996;1523.
29. Neefjes J.J., Momburg F. Cell biology of antigen presentation. Curr Opin Immunol. 5:1993;27.
30. Müller M., Zhou J., Reed T.D., Rittmüller C., Burger A., Gabelsberger J., Braspenning J., Gissmann L. Chimeric papillomavirus-like particles. Virology. 234:1997;93.
31. Schäfer K., Müller M., Faath S., Henn A., Osen W., Zentgraf H., Brenner A., Gissmann L., Jochmus I. Immune response to HPV 16 L1/E7 chimeric virus-like particles. induction of cytotoxic T cells and specific tumor protection Int J Cancer. 81:1999;881.